Last updated: September 4, 2026
Lomustine is an established oral nitrosourea with a relatively simple dosage form and limited active-ingredient differentiation. Commercial opportunity is concentrated in capsule robustness, moisture protection, dose flexibility, hazardous-drug handling, pediatric administration, global supply, and lifecycle formulations rather than in a conventional new chemical entity strategy. The leading U.S. product, Gleostine, is marketed by NextSource Pharma and is supplied as 10 mg, 40 mg, and 100 mg capsules.
What is lomustine and how is it supplied?
Lomustine, also known as CCNU, is an oral alkylating agent used for brain tumors and Hodgkin lymphoma after failure of primary therapy. The drug is administered as a single oral dose every six weeks, with dosing based on body surface area and hematologic recovery. Its extended dosing interval differentiates it from many continuously administered oral oncology products.
| Attribute |
Lomustine |
| Active ingredient |
Lomustine |
| Chemical designation |
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea |
| Drug class |
Nitrosourea alkylating agent |
| Route |
Oral |
| U.S. reference product |
Gleostine |
| U.S. NDA |
NDA 017557 |
| Strengths |
10 mg, 40 mg, 100 mg |
| Main indications |
Brain tumors; Hodgkin lymphoma after failure of primary therapy |
| Dosing pattern |
Single dose, generally repeated every six weeks |
| Regulatory status |
Approved prescription drug |
| Handling category |
Hazardous antineoplastic drug |
The product is supplied in hard capsules. The FDA label requires administration as a single dose and warns against repeated dosing at intervals shorter than six weeks because of delayed and cumulative bone-marrow toxicity (U.S. Food and Drug Administration [FDA], 2023).
What excipients are used in Gleostine capsules?
Gleostine capsules use conventional capsule excipients, colorants, and shell materials. The label identifies the dosage form as a hard gelatin capsule and lists inactive ingredients by strength. The product uses different capsule colors to distinguish dose levels, reducing medication-error risk in a drug with substantial delayed hematologic toxicity.
Exact excipient composition can vary by strength and market presentation. The relevant excipient functions are:
| Excipient function |
Commercial purpose |
| Gelatin capsule shell |
Provides a dry, unit-dose container for lomustine powder |
| Capsule colorants |
Differentiates 10 mg, 40 mg, and 100 mg strengths |
| Titanium dioxide or other opacifier |
Controls capsule appearance and light exposure |
| Fill diluent |
Provides bulk and improves dose uniformity |
| Glidant or lubricant |
Supports powder flow and capsule filling |
| Moisture-control packaging |
Protects a moisture-sensitive oncology product |
Lomustine is a small, lipophilic molecule with limited aqueous solubility. A dry powder-filled capsule is therefore more commercially practical than an aqueous liquid or conventional solution. Excipients should be selected to maintain chemical stability, reduce powder segregation, support content uniformity, and avoid accelerated degradation under humidity stress.
The product’s principal excipient constraint is not gastrointestinal tolerability. It is physical and chemical stability during manufacturing, storage, dispensing, and handling.
Which excipient attributes matter most for lomustine?
Moisture control
Moisture management is the highest-value excipient and packaging consideration. A capsule formulation should minimize water activity in the fill and limit moisture migration through the shell. Formulators should evaluate:
- Low-moisture diluents
- Desiccant-compatible packaging
- High-barrier bottles or blisters
- Water activity of the finished capsule
- Gelatin-shell moisture transfer
- Stability under ICH long-term and accelerated conditions
Microcrystalline cellulose, anhydrous lactose, dibasic calcium phosphate, and selected co-processed excipients can provide different combinations of flow, compressibility, and moisture performance. The preferred choice depends on lomustine loading, powder density, and compatibility data.
Content uniformity
Lomustine capsules are administered in a narrow therapeutic context, and dose escalation or repetition is constrained by blood counts. A formulation must achieve robust content uniformity across the full capsule-filling run, particularly for the 10 mg strength.
High-potency handling also affects manufacturing design. Low-dose capsules can be vulnerable to segregation when the active ingredient has a substantially different particle size or density from the excipient blend. Particle engineering, geometric dilution, ordered mixing, or a controlled granulation step may improve uniformity.
Capsule-shell performance
Gelatin is familiar, inexpensive, and accepted in the reference product. Hydroxypropyl methylcellulose, or HPMC, could support a differentiated capsule platform where vegetarian labeling, shell moisture performance, or improved supply resilience is commercially important.
An HPMC switch would create development work involving:
- Comparative dissolution
- Capsule-shell moisture behavior
- Mechanical integrity
- Stability after packaging
- Compatibility with the fill blend
- Bioequivalence under an abbreviated application
The change would have commercial value only if it solves a defined problem, such as gelatin supply volatility, animal-origin restrictions, or improved stability.
Color and medication-error control
Strength-specific capsule colors are operationally important. Lomustine toxicity is delayed, and administration errors may not be recognized immediately. Distinctive color coding, printed strength identification, and clear carton labeling can reduce selection errors across the 10 mg, 40 mg, and 100 mg presentations.
A generic product that uses a different color system may still comply with FDA requirements, but it should preserve rapid visual differentiation and avoid look-alike characteristics with other oral oncology capsules.
What formulations are protected or commercially differentiated?
The strongest practical opportunities are formulation improvements that address administration, stability, or dose flexibility. Potential product concepts include:
| Formulation concept |
Commercial rationale |
Main development barrier |
| Moisture-optimized powder-filled capsule |
Longer shelf life and lower stability risk |
Must demonstrate equivalent performance |
| HPMC capsule |
Animal-origin-free or supply-chain alternative |
Shell compatibility and bioequivalence |
| Low-dust capsule system |
Improved occupational handling |
Requires containment and process validation |
| Pediatric mini-capsule |
Easier swallowing and lower dose increments |
Pediatric bioavailability and dosing data |
| Sprinkle or dispersible capsule |
Administration for patients unable to swallow |
Hazardous-drug exposure and dose uniformity |
| Unit-dose blister |
Better dispensing control and adherence |
Packaging cost and stability validation |
| Multi-strength packaging platform |
Reduces pharmacy selection errors |
Artwork, serialization, and inventory complexity |
A liquid formulation is less attractive because lomustine has limited water solubility, is cytotoxic, and has a relatively infrequent dosing schedule. A liquid or suspension would introduce chemical stability, preservative, dose-measurement, and caregiver exposure issues.
How strong is the patent estate for lomustine?
Lomustine has an old active ingredient and an established oral capsule presentation. The original compound and early product protections are expected to have expired. The commercial defense of the product is therefore based primarily on regulatory requirements, manufacturing know-how, supply reliability, trademarks, and any currently listed product-specific patents rather than basic molecule protection.
| IP category |
Expected position |
| Lomustine compound patent |
Expired |
| Original capsule formulation |
Expired or commercially nonexclusive |
| Basic oral use claims |
Generally mature and vulnerable to prior art |
| Modern formulation claims |
Potentially available if technically distinct |
| Manufacturing process claims |
Possible, but narrow and process-specific |
| Trademark protection |
Available for brand names such as Gleostine |
| Trade secrets |
Relevant to powder handling, blending, containment, and stability |
| Regulatory exclusivity |
No current new-drug exclusivity expected from the original approval |
FDA’s Orange Book should be used to confirm current patent listings for NDA 017557. A sponsor seeking a U.S. generic would generally evaluate an ANDA pathway, including Paragraph IV certification if any unexpired listed patents are identified (FDA, 2024a).
When does lomustine lose exclusivity?
Lomustine’s foundational market exclusivity has already expired. The key timing issue is not loss of original compound exclusivity but the existence of any later-listed patents, pediatric exclusivity, orphan exclusivity, or regulatory barriers associated with the marketed product.
The commercial timeline is:
| Milestone |
Timing or status |
| Original lomustine development |
1960s-1970s |
| U.S. NDA approval |
1976 |
| Original molecule and early formulation protection |
Expired |
| Current branded product |
Gleostine |
| Generic pathway |
ANDA, subject to Orange Book review |
| New excipient formulation |
Could obtain patent protection if novel and nonobvious |
| New delivery system |
Could support method, composition, or device claims |
| Biosimilar pathway |
Not applicable |
Because lomustine is a chemically synthesized small molecule, biosimilar risk does not apply. The competitive issue is generic entry, not biosimilar substitution.
Which companies are challenging lomustine exclusivity?
The generic competitive field is structurally more important than the biosimilar field. Potential ANDA sponsors include established generic manufacturers with oncology capsule capabilities, high-containment facilities, and experience with hazardous active pharmaceutical ingredients.
Publicly confirmed Paragraph IV litigation, settlement terms, and ANDA applicant identities should be assessed through FDA litigation records, federal court dockets, and current Orange Book data. No assumption should be made that a generic competitor has market authorization merely because lomustine is an old drug. The applicant must still satisfy pharmaceutical equivalence, bioequivalence, manufacturing, stability, labeling, and hazardous-drug controls.
A generic entrant would likely compete on:
- Wholesale acquisition price
- Reliable availability of all three strengths
- Pharmacy inventory support
- Unit-dose packaging
- Hospital contracting
- Patient-assistance programs
- Ability to maintain supply during oncology shortages
What FDA regulatory status affects excipient strategy?
Lomustine is approved under a conventional NDA framework, and a generic sponsor would typically rely on an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A formulation that changes capsule shell, fill excipients, colorants, packaging, or release characteristics may remain suitable for an ANDA, but the product must still meet applicable FDA requirements.
Critical regulatory controls include:
- Same active ingredient and dosage form.
- Equivalent strength and route of administration.
- Comparable labeling, subject to permitted generic changes.
- Demonstrated bioequivalence.
- Acceptable dissolution behavior.
- Stability through the proposed shelf life.
- Validated content uniformity.
- Compliance with current good manufacturing practice.
- Appropriate containment for a cytotoxic compound.
A materially different dosage form, such as a liquid suspension or modified-release product, would likely require a different regulatory strategy and could move beyond a straightforward ANDA.
What generic launch risks exist for lomustine?
The main launch risks are operational rather than scientific.
Supply and manufacturing risk
Lomustine requires controlled handling because it is a cytotoxic alkylating agent. Facilities must manage operator exposure, cross-contamination, waste, cleaning validation, and environmental controls. These requirements reduce the number of qualified manufacturers.
Dose-strength risk
A sponsor must support 10 mg, 40 mg, and 100 mg strengths or explain the commercial rationale for a limited presentation. Omitting the 10 mg strength can reduce pharmacy utility because dosing is based on body surface area and may require fine dose adjustment.
Stability risk
A generic capsule can fail commercially if it has a shorter shelf life, requires special storage, or shows moisture-related degradation. Stability data should be generated early, particularly for capsule-shell and packaging changes.
Market-size risk
Lomustine is a niche oncology product. Development costs for hazardous-drug manufacturing, bioequivalence, and multiple strengths may be significant relative to addressable volume. A sponsor needs a credible reimbursement and supply strategy before committing to a full-strength portfolio.
What commercial opportunities exist beyond a standard generic?
Pediatric and dysphagia-focused products
Brain-tumor patients may include children or patients with impaired swallowing. Mini-capsules, carefully controlled sprinkle systems, or pharmacist-administered dose adaptations could address an unmet administration need. These products require strict control of powder release because opening a cytotoxic capsule can expose caregivers and healthcare workers.
Hospital and specialty-pharmacy supply
A dependable three-strength portfolio can support oncology wholesalers, specialty pharmacies, and hospital systems. Packaging that reduces dispensing errors has commercial value even without clinical differentiation.
International formulations
Some markets may prefer gelatin-free shells, blister packaging, or multilingual strength coding. A global platform using the same fill blend with region-specific shells and packaging could reduce development duplication.
Lifecycle patents
New patentable subject matter may exist in:
- Low-moisture excipient systems
- Specific particle-size distributions
- Capsule-shell compositions
- High-barrier packaging combinations
- Improved dose-uniformity processes
- Pediatric dosage forms
- Hazardous-drug containment systems
- Stability-enhancing manufacturing processes
Patent strength would depend on comparative data showing a measurable technical effect. Broad claims covering "lomustine plus a conventional diluent" would face substantial prior-art risk because the drug and capsule format are longstanding.
How does lomustine compare with competing oral oncology drugs?
Lomustine competes clinically with other therapies used in glioma and relapsed brain tumors, including temozolomide and selected targeted or biologic treatments depending on tumor type and treatment line. Its commercial profile differs from newer agents:
| Factor |
Lomustine |
Newer oral oncology products |
| Dosing |
Intermittent single dose |
Often daily or cyclic |
| Dosage form |
Conventional capsule |
Capsule, tablet, or specialized delivery |
| Patent position |
Mature |
Often active composition and method patents |
| Excipient differentiation |
Limited but feasible |
Frequently linked to complex formulations |
| Toxicity management |
Delayed marrow suppression |
Product-specific |
| Generic exposure |
High |
Often limited before patent expiry |
| Commercial opportunity |
Supply, price, packaging, administration |
Clinical differentiation and patent lifecycle |
Lomustine’s low patent barrier increases generic risk, but its hazardous manufacturing requirements and small market can limit the number of credible entrants.
What patent litigation and settlement issues matter?
For an old small-molecule capsule, litigation is most likely to arise from later formulation, manufacturing, or branded-product patents rather than the lomustine molecule itself. A Paragraph IV challenge could target any unexpired Orange Book-listed patent. Settlement agreements may include delayed entry, authorized generic rights, license terms, or restrictions on specific presentations.
The relevant diligence points are:
- Current Orange Book patents for NDA 017557
- FDA-listed exclusivity codes
- ANDA litigation under the Hatch-Waxman framework
- Federal court docket activity
- Authorized generic arrangements
- Product-specific manufacturing patents
- Brand and generic supply agreements
Key Takeaways
- Lomustine is a mature oral nitrosourea supplied as 10 mg, 40 mg, and 100 mg hard capsules.
- Excipient strategy should prioritize moisture control, content uniformity, capsule-shell compatibility, and hazardous-drug manufacturing.
- HPMC capsules, unit-dose blistering, pediatric mini-capsules, and stability-enhanced fills offer the clearest lifecycle opportunities.
- Foundational lomustine patent protection has expired; commercial barriers are more likely to involve regulatory compliance, manufacturing capability, and supply reliability.
- Biosimilar competition is irrelevant because lomustine is a synthetic small molecule.
- Generic entry risk is real, but the niche market and cytotoxic handling requirements may limit the number of viable competitors.
- Strong lifecycle patents require comparative technical data, not merely substitution of a familiar excipient.
- FDA Orange Book and litigation records determine the current U.S. patent and Paragraph IV position.
FAQs
Is lomustine a good candidate for an excipient-based reformulation?
Yes, but the opportunity is narrow. The strongest candidates are moisture-optimized capsule fills, alternative capsule shells, pediatric presentations, and packaging systems that reduce handling and dispensing risk.
Can lomustine be formulated as a liquid?
Technically possible, but commercially difficult. Limited aqueous solubility, cytotoxicity, chemical stability, preservative requirements, and caregiver exposure make a liquid less attractive than a dry capsule.
Does lomustine have biosimilar competition?
No. Lomustine is a chemically synthesized small molecule. Competition would occur through generic drug applications rather than biosimilar applications.
Can a gelatin-free lomustine capsule receive patent protection?
Potentially. A patent would require a novel and nonobvious capsule-shell or formulation combination, supported by technical advantages such as improved stability, reduced moisture uptake, or manufacturing performance.
What is the largest commercial risk for a lomustine generic?
The largest risk is achieving sustainable supply at a viable margin. Cytotoxic containment, multiple strengths, stability requirements, and a relatively small oncology market can make manufacturing economics challenging.
References
-
DailyMed. (2023). Gleostine: Lomustine capsule prescribing information. U.S. National Library of Medicine.
-
National Cancer Institute. (2024). Lomustine. National Cancer Institute Drug Dictionary.
-
U.S. Food and Drug Administration. (2023). Gleostine (lomustine) capsules: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024b). FDA guidance for industry: ANDAs for certain highly purified synthetic peptides and complex drug products. FDA.
-
National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings. Centers for Disease Control and Prevention.
